pituitary gland
Enable an AI agent to recognise a pituitary gland, assess its anatomical integrity and endocrine function, and identify evidence and clinical authority needed before action.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
Researched by: Codex + Grok
Purpose and description
Enable an AI agent to recognise a pituitary gland, assess its anatomical integrity and endocrine function, and identify evidence and clinical authority needed before action.
The pituitary gland (hypophysis) is a pea-sized endocrine organ in the sella turcica of the sphenoid, suspended from the hypothalamus by the infundibulum, that secretes tropic and effector hormones from an anterior adenohypophysis of oral-ectoderm origin and a posterior neurohypophysis of neural origin, thereby coordinating growth, metabolism, reproduction, stress, and water balance.
It can be Associate imaging, laboratory results and operative or pathology reports with the correct gland and compartment.; Compare gland morphology and endocrine evidence across time using compatible methods and physiological context.; Identify missing paired hormone measurements or specialist assessments needed to resolve a pituitary-specific uncertainty.; Flag recorded acute structural or endocrine concerns for clinician review under an applicable clinical protocol.; Support authorised clinicians in assessing intervention feasibility by exposing residual function, adjacent anatomy and prior treatment.; Track whether a pituitary-directed intervention achieved its recorded objective and whether function changed afterward..
Distinguishing features
Check anatomical position and continuity with the hypothalamic stalk: the human pituitary normally occupies the sella turcica; displacement or ectopia requires supporting evidence rather than automatic exclusion. [Anatomical reference](https://www.ncbi.nlm.nih.gov/books/NBK425703/)
Distinguish the gland from the hypothalamus by identifying its anterior endocrine tissue and posterior neural compartment, rather than treating the connected structures as one organ. [Anatomical reference](https://www.ncbi.nlm.nih.gov/books/NBK425703/)
Distinguish posterior pituitary release from hormone synthesis: vasopressin and oxytocin originate in hypothalamic neurons and reach posterior pituitary terminals. [Functional reference](https://www.ncbi.nlm.nih.gov/books/NBK27/)
Distinguish the whole gland from an adjacent or intrapituitary mass by recording identifiable gland tissue, lesion boundaries and displacement; a sellar mass alone does not establish gland identity.
Scope
+ Identity, species, anatomical location and developmental variants of the gland
+ Anterior and posterior compartments, residual tissue and their relationship to the pituitary stalk
+ Pituitary hormone production or release and evidence of preserved, deficient or excessive function
+ Gland enlargement, focal abnormalities, tissue injury and effects on adjacent structures
+ Pituitary-specific assessment, intervention constraints and longitudinal follow-up
- The hypothalamus as an independently modelled brain structure
- Whole-body endocrine regulation and downstream thyroid, adrenal and gonadal organ models
- Pituitary tumours as independently classified diseases, beyond their effects on this gland
- The optic apparatus, cavernous sinuses and skull base as separate anatomical entities
- Laboratory assays, imaging equipment, medicines and surgical procedures as independent things
- Patient-wide diagnosis, treatment planning and consent records beyond linked pituitary decisions
Characteristics
- Organism and physiological context
- Linked organism; species, age, reproductive state and relevant physiological context Determines which anatomical expectations and hormone reference intervals apply.
- Location and compartment identification
- Sellar, ectopic, displaced or indeterminate; anterior, posterior and stalk structures identified or unresolved Supports organ recognition and localisation of abnormalities.
- Gland dimensions
- Three orthogonal dimensions in mm; volume in mm³ if measured; modality, date and segmentation method Supports comparison over time without imposing one normal size across all contexts.
- Residual tissue and structural integrity
- Describe preserved, compressed, atrophic, injured, resected or unassessed tissue by compartment Separates the amount and condition of gland tissue from the size of any lesion.
- Anterior pituitary hormone observations
- ACTH, TSH, GH, prolactin, LH and FSH; laboratory-reported units, sampling time and assay-specific reference intervals Records the principal anterior outputs while preserving interpretation context. [Functional reference](https://www.ncbi.nlm.nih.gov/books/NBK27/)
- Endocrine axis interpretation
- Per axis: preserved, suspected deficient, confirmed deficient, suspected excessive, confirmed excessive or indeterminate Prevents one hormone measurement from being treated as a verdict on the entire gland.
- Water-balance evidence
- Linked serum sodium in mmol/L, serum and urine osmolality in mOsm/kg, and urine output in mL/day or mL/kg/hour Provides evidence relevant to vasopressin function while retaining alternative explanations.
- Stalk and hypothalamic connection
- Continuity, displacement, thickening, interruption or uncertain appearance; supporting examination Connects structural observations with hypotheses about impaired regulation or hormone transport.
- Relationship to adjacent structures
- Reported separation, contact, displacement or compression involving optic apparatus and cavernous sinus structures Makes local consequences visible independently of endocrine function.
- Intervention exposure
- Linked operation, irradiation, medication or other intervention; date, target and observed effects Supports attribution of changes and distinguishes treated state from intrinsic function.
Also called
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 18 findings · 35 questions.
Gland identity and compartments Establish which organ is represented and how its constituent structures are recognised.
A sellar location or endocrine abnormality alone cannot identify the gland or its affected compartment.
Organ identification
Anchor identity to the organism and observed anatomy.
Pituitary identity evidence
Record the evidence identifying this structure as the pituitary, including atypical location or incomplete visualisation.
- Which organism and species does this gland belong to, and what evidence identifies it as the pituitary? definition
- Which imaging, operative or anatomical record establishes its location and identity? provenance
Compartment boundaries
Separate gland compartments from the stalk, hypothalamus and any lesion.
Identified pituitary tissue
Record anterior and posterior tissue identification and the explicit boundary convention for stalk involvement.
- Which anterior and posterior tissues are identifiable, absent, displaced or unresolved? measurement
- Where does this record place the boundary between the gland, stalk and hypothalamus? boundary
- Can a reported lesion be distinguished from preserved gland tissue? boundary
Sellar structure and local effects Describe gland morphology, tissue integrity and relationships that affect nearby structures.
Structural abnormalities can matter independently of whether hormone secretion appears preserved.
Gland morphology
Record dimensions and structural changes with reproducible observation methods.
Morphology and residual tissue
Distinguish total gland dimensions, focal abnormalities and remaining recognisable tissue.
- What are the gland dimensions, and which modality, planes and date produced them? measurement
- What evidence describes focal lesions, compression, haemorrhage, infarction or loss of tissue, and how certain is each interpretation? provenance
Parasellar relationships
Connect gland or lesion extension with nearby anatomy and observed consequences.
Adjacent structure involvement
Record reported contact or compression separately from demonstrated visual or neurological impairment.
- What relationship is reported between the gland or associated lesion and the optic apparatus or cavernous sinus structures? boundary
- Which visual-field, acuity or cranial-nerve observations establish a functional consequence? measurement
- Does the documented finding meet an applicable clinician-defined escalation criterion? action
Anterior pituitary output Assess anterior endocrine function by axis and by the context of the evidence.
Pituitary output must be interpreted alongside downstream responses, feedback and sampling conditions.
Axis-specific function
Represent each endocrine axis independently before forming an organ-level judgement.
Output and target response
Pair pituitary observations with relevant target-organ or response markers and retain uncertain attribution.
- What do ACTH with cortisol, TSH with free T4, and LH or FSH with relevant gonadal markers show in their sampling context? measurement
- What evidence supports the assessment of GH function and prolactin secretion? measurement
- Does the evidence localise dysfunction to the pituitary, hypothalamus, target organ or an unresolved combination? boundary
Endocrine test interpretation
Preserve factors that determine whether basal or dynamic measurements support a conclusion.
Sampling and test validity
Record assay, timing, physiological state, medication exposure and any stimulation or suppression protocol.
- Which sampling times, reference intervals, medicines and physiological conditions affect interpretation? provenance
- If dynamic testing was performed, what protocol, timed results and interpretation criteria were used? measurement
- What unresolved question requires a clinician to consider repeat or dynamic testing? action
Posterior pituitary and stalk function Represent neurohypophyseal release and the integrity of hypothalamic connections.
Posterior release and stalk-mediated regulation require evidence distinct from anterior hormone production.
Neurohypophyseal function
Assess evidence concerning vasopressin-mediated water balance and context-specific oxytocin function.
Posterior release evidence
Record measured consequences and specialist interpretations without assuming that a symptom proves posterior pituitary failure.
- What paired water-balance observations, fluid intake and relevant treatment exposures support assessment of vasopressin function? measurement
- What evidence separates a central release problem from renal response, intake or other causes? boundary
- Where clinically relevant, what evidence supports an oxytocin-related functional assessment, and what remains unmeasured? measurement
Hypothalamic connections
Assess stalk findings and their possible effects on transport and anterior regulation.
Stalk integrity and attribution
Keep observed stalk abnormalities separate from hypotheses about their endocrine effects.
- What examination documents stalk continuity, displacement, thickening or interruption? provenance
- Which endocrine findings are attributed to altered hypothalamic input, and what supports that attribution? boundary
Pituitary course and action Connect changes in gland state with prior interventions, follow-up needs and authorised clinical decisions.
Structural improvement, endocrine recovery and treatment dependence must be tracked separately.
Intervention and reassessment
Record why a pituitary-directed intervention occurred and what changed afterward.
Treatment effects and residual function
Link intervention objectives to subsequent morphology, endocrine function and replacement dependence.
- Which operation, irradiation or medication affected this gland, and what was its documented objective? provenance
- What changed in gland structure and each assessed endocrine function after the intervention? measurement
- Which observations reflect hormone replacement or suppression rather than demonstrated intrinsic gland function? boundary
Clinical action constraints
Identify the evidence, authority and anatomical or endocrine constraints relevant to a proposed action.
Pituitary decision readiness
Record whether observation, reassessment or intervention is supported by a documented clinical plan.
- What pituitary-specific uncertainty, change or risk is the proposed action intended to address? action
- Which missing endocrine assessments, adjacent-structure evaluations or prior-treatment records could change that decision? action
- Which responsible clinician, consent record and applicable protocol authorise the action and define follow-up or escalation? provenance
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Kinds and varieties
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Adenohypophysis (anterior pituitary: pars distalis, and in many species pars intermedia and pars tuberalis)
- Neurohypophysis (posterior pituitary: pars nervosa plus infundibular stalk)
- Pars intermedia (intermediate lobe; vestigial or thin in adult humans, well developed in many other mammals)
- Pars tuberalis (collar of adenohypophyseal tissue around the infundibulum)
- Ectopic / pharyngeal pituitary remnants (Rathke-pouch rests along the craniopharyngeal canal)
- Pituitary adenoma (functional vs non-functioning; microadenoma vs macroadenoma - the main clinical 'kinds' of the gland as a diseased organ)
- Fetal vs adult pituitary (vascular and cellular composition change after birth; intermediate lobe regresses in humans)
- Veterinary / comparative pituitary (distinct pars intermedia and seasonal pars tuberalis function in horses, sheep, and other mammals)
- Which of these kinds and varieties hold for the sense of pituitary gland this model covers, and on what evidence? provenance
Identifiers and schemes
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Wikidata - Q155201 - Item 'pituitary gland'.
- FMA - FMA:13889 - Foundational Model of Anatomy class for hypophysis.
- UBERON - UBERON:0000007 - Uber-anatomy ontology 'pituitary gland'.
- MeSH - D010902 - Medical Subject Heading 'Pituitary Gland'.
- Terminologia Anatomica - TA98 A11.1.00.001 / TA2 3853 - Official anatomical name hypophysis / glandula pituitaria.
- SNOMED CT - 56329008 - Body-structure concept 'Pituitary structure'.
- ICD-11 - 5A6* (block: disorders of the pituitary gland) - Disease classification of the organ, not the organ itself; WHO MMS.
- Which of these identifiers and schemes hold for the sense of pituitary gland this model covers, and on what evidence? provenance
Standards and regulation
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Terminologia Anatomica (TA98/TA2) - Federative International Programme for Anatomical Terminology (FIPAT / IFAA): official names hypophysis, adenohypophysis, neurohypophysis.
- WHO ICD-11 chapter 5A60-5A6Z - World Health Organization: classification of hyperfunction, hypofunction, and neoplasms of the pituitary.
- Endocrine Society Clinical Practice Guidelines (acromegaly, Cushing, hypopituitarism, prolactinoma) - Endocrine Society: diagnostic thresholds and treatment pathways.
- WHO Classification of Tumours of Endocrine Organs / 5th-edition CNS and endocrine volumes - IARC/WHO: histopathology of pituitary neuroendocrine tumours (PitNETs).
- Human Tissue Act 2004 (England, Wales, Northern Ireland) and equivalent EU/US tissue rules - national competent authorities: pituitary as relevant material for research and transplant (historical cadaveric GH).
- EMA/FDA product monographs for recombinant GH, desmopressin, dopamine agonists, somatostatin analogues, and ACTH/cosyntropin tests - EMA and FDA: licensed uses that act on or replace pituitary function.
- Which of these standards and regulation hold for the sense of pituitary gland this model covers, and on what evidence? provenance
Real-world use
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Target of MRI (sella protocol) and inferior-petrosal-sinus sampling in suspected Cushing disease or adenoma.
- Source of clinically measured tropic hormones (TSH, ACTH, GH, PRL, LH/FSH) in blood panels.
- Surgical field in transsphenoidal adenomectomy and hypophysectomy.
- Historical source of cadaveric human growth hormone (withdrawn after iatrogenic CJD).
- Comparative-anatomy and veterinary object (equine pituitary pars intermedia dysfunction / PPID).
- Teaching specimen in anatomy and histology (Rathke-pouch remnant, acidophils/basophils/chromophobes).
- Which of these real-world use hold for the sense of pituitary gland this model covers, and on what evidence? provenance
Typical measurements
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Gland mass (adult human) - 0.5-0.9 (larger in parous women, up to ~1.0) - g
- Gland dimensions (adult, MRI/autopsy) - height 3-8; width ~10; anteroposterior ~8 (height higher in young women and pregnancy) - mm
- Serum prolactin (non-pregnant adult) - roughly 5-25 (assay-dependent; pregnancy much higher) - µg/L
- IGF-1 / GH axis - age- and sex-specific IGF-1 SDS; nadir GH on OGTT typically <0.4 for excluding acromegaly (assay-dependent) - µg/L (GH); nmol/L or µg/L (IGF-1)
- Morning serum cortisol as ACTH-axis screen - failure suggested if <~100-140; pass often >~400-500 (cut-offs guideline- and assay-dependent) - nmol/L
- Adenoma size class - microadenoma <10; macroadenoma ≥10; giant often ≥40 - mm
- Which of these typical measurements hold for the sense of pituitary gland this model covers, and on what evidence? provenance
Failure modes and hazards
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Hypopituitarism (partial or pan-) after adenoma, surgery, radiation, apoplexy, Sheehan syndrome, or infiltration - risk of adrenal crisis if ACTH is lost.
- Hormone hypersecretion: prolactinoma (hypogonadism, galactorrhea), GH (acromegaly/gigantism), ACTH (Cushing disease), TSH-oma, gonadotrophinoma.
- Mass effect: optic-chiasm compression (bitemporal hemianopia), cranial-nerve palsy in cavernous sinus, hydrocephalus, headache.
- Pituitary apoplexy: acute haemorrhage or infarction - neurosurgical emergency.
- Diabetes insipidus from posterior-lobe or stalk injury (central DI).
- Iatrogenic: transsphenoidal CSF leak, meningitis, carotid injury; historical cadaveric GH transmitting prion disease (iCJD).
- Empty-sella and stalk interruption syndromes with variable endocrine deficit.
- Drug effects: glucocorticoids, opioids, and immune-checkpoint inhibitors causing secondary adrenal insufficiency; dopamine antagonists raising prolactin.
- Which of these failure modes and hazards hold for the sense of pituitary gland this model covers, and on what evidence? provenance
Regional variation
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- English clinical usage prefers 'pituitary'; many European anatomical texts still lead with 'hypophysis' (TA).
- Adult human pars intermedia is a thin residual cleft; it is a full lobe in most other mammals - veterinary diagnosis (PPID in horses) does not map 1:1 to human 'intermediate-lobe' disease.
- Access to inferior-petrosal-sinus sampling, stereotactic radiosurgery, and pituitary MDTs is concentrated in tertiary centres; much of the world diagnoses by basal hormones and non-specialist MRI only.
- SI units (nmol/L cortisol, mIU/L gonadotrophins) vs US conventional units (µg/dL, mIU/mL) change numeric cut-offs in guidelines.
- Which of these regional variation hold for the sense of pituitary gland this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Hypothalamus - Hypothalamus is diencephalic neural tissue that releases releasing/inhibiting factors into the portal system and makes ADH/oxytocin; the pituitary is the sella organ that stores (posterior) or secretes tropic hormones (anterior). MRI: above vs inside the sella, separated by the diaphragma sellae / stalk.
- Pineal gland - Pineal is a midline epithalamic melatonin organ in the quadrigeminal cistern, not in the sella; no adenohypophyseal histology.
- Rathke cleft cyst / craniopharyngioma - Both arise from Rathke-pouch remnants; they are cystic/epithelial tumours adjacent to or compressing the gland, not the gland's native anterior/posterior parenchyma. Histology (adamantinomatous/papillary craniopharyngioma or simple Rathke epithelium) and MRI (T1-bright proteinaceous cyst vs enhancing adenoma) separate them.
- Sella turcica / cavernous sinus contents - Bone and venous/neural envelope around the gland (ICA, CN III-VI); invasion is diagnosed when adenoma crosses the thin medial cavernous wall (Knosp grade), not when the gland merely sits in the sella.
- Primary hypothyroidism with thyrotroph hyperplasia - Looks like a pituitary mass but TSH is high with low free T4; the 'mass' regresses on levothyroxine, unlike a primary TSH-secreting adenoma (high T4 with unsuppressed TSH).
- Posterior pituitary bright spot vs lipoma/haemorrhage - Normal T1-hyperintense ADH-neurosecretory granules in the posterior lobe; lost in central DI. Distinguish from fat (fat-sat) and from haemorrhage (evolution on T1/T2, clinical apoplexy).
- Which of these neighbouring kinds and how to tell them apart hold for the sense of pituitary gland this model covers, and on what evidence? provenance
Sources
- Pituitary Gland - Clinical anatomy, hormone list, and disease spectrum used for definition, kinds, measurements, and failure modes.
- Pituitary gland - Standard anatomical partition (adeno- vs neurohypophysis), embryology, and neighbour structures.
- pituitary gland (Q155201) - Canonical identifiers (Wikidata, FMA, UBERON, MeSH, TA) and cross-ontology mapping.
- ICD-11 - Diseases of the pituitary gland - Regulatory/classification codes for pituitary disorders used in standards_and_regulation.
What the second pass must settle
- Does the registry intend a human-only model or a cross-species model requiring different compartment descriptions and endocrine expectations?
- Does an existing Vercy world model already own this concept, requiring this registry entry to link to it rather than create a second model?
- Which anatomical convention should govern inclusion of the infundibulum and pars intermedia within this organ model?
- Which authoritative clinical references and local protocols should supply context-specific reference intervals, dynamic-test criteria and escalation thresholds?
- What evidence standard should establish intrinsic endocrine recovery after treatment, particularly when replacement or suppressive medicines complicate interpretation?